Cosmo is a specialty pharmaceutical company focused in treating selected Gastrointestinal and Skin Disorders. Discover more about our strategic approaches.
The company is developing a range of pharmaceutical products that are based on new chemical entities and are targeted on skin diseases that can be topically treated.
Inflammatory Bowel Diseases (IBD) are a group of chronic, progressive, recurring and debilitating disorders characterized by severe damage of the gastro-intestinal tract.
Cosmo informs on change of its international securities identification number ISIN
Cosmo shareholders approve change of registered seat
Cosmo board approves change of registered seat
Read all news articles
Cosmo is a specialty pharmaceutical company that aims to become a global leader in the market of optimized therapies for selected gastro-intestinal diseases. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for gastro-intestinal diseases.
Read more about us
Share price information
07/06/2016 - 09/06/2016
Jefferies Global Health Care Conference in New York
Get in touch with us today.
© 2016 Cosmo pharmaceuticals